Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

46.83 -3.45 (-6.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,610,677
Open 50.42
Bid (Size) 46.84 (19)
Ask (Size) 46.88 (1)
Prev. Close 50.28
Today's Range 46.57 - 50.90
52wk Range 46.57 - 170.47
Shares Outstanding 385,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over upcoming COVID and RSV sales. 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
Smart Money Is Betting Big In MRNA Options
Via Benzinga

Performance

YTD
-58.37%
-58.37%
1 Month
-17.60%
-17.60%
3 Month
-42.39%
-42.39%
6 Month
-62.74%
-62.74%
1 Year
-33.15%
-33.15%

More News

Read More
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Via The Motley Fool
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Via ACCESSWIRE
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Via Benzinga
Topics Government
Exposures Political
Moderna (MRNA) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Via ACCESSWIRE
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
In-Depth Examination Of 15 Analyst Recommendations For Moderna
Via Benzinga
Moderna Q3 Revenue Beats On Updated COVID-19 Vaccine, Slashes Expenses For 2024
Via Benzinga
Exposures COVID-19
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?
Via Investor's Business Daily
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
Via Benzinga
Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.
Via Benzinga
Topics Government
Exposures Political
Moderna to Present at Upcoming Conferences in November 2024
Via ACCESSWIRE
Behind the Scenes of Moderna's Latest Options Trends
Via Benzinga
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
These 10 Stocks Were S&P 500's Top Performers In Biden's First Year: Could The Trend Continue If Harris Wins 2024 Election?
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Moderna Stock Trading Higher On Monday?
Via Benzinga
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Large-Cap Stocks In Trouble - Sunday, Oct. 27
Via Talk Markets
Moderna Named a Top Employer by Science for Tenth Consecutive Year
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.